Innocan Pharma's NYSE Leap: CBD Therapeutics Enter the Big Leagues

HERZLIA, Israel and CALGARY, AB – January 02, 2026 – Innocan Pharma Corporation is poised for a major strategic pivot, announcing its anticipated listing on the NYSE American stock exchange on or around January 7, 2026. The move, which will transition the pharmaceutical technology company from the OTCQB market to a major U.S. exchange, signals a new chapter in its quest to legitimize and fund its innovative CBD-based drug delivery platforms.

In conjunction with the listing, Innocan is launching a public offering of securities, a move designed to raise capital and broaden its investor base. This dual action underscores the company's ambition to accelerate its growth, moving from a development-stage entity to a significant player in both the pharmaceutical and wellness sectors. As Innocan prepares to trade under the new symbols "INNP" and "INNPW" for its common shares and warrants, the financial world watches to see if this uplisting can translate its technological promise into market success.

A Strategic Uplist to Wall Street

The transition to the NYSE American is more than a symbolic gesture; it is a calculated maneuver to enhance liquidity, increase visibility, and attract institutional investment that often shies away from over-the-counter markets. The listing is subject to the final approval of the company's application and its continued compliance with the exchange's rigorous standards.

To meet the exchange's requirements and prepare for the offering, Innocan executed a 65-for-1 reverse share split in late 2025, consolidating its approximately 292.4 million shares to a more manageable 4.5 million. The concurrent offering, managed by ThinkEquity LLC as the sole book-running manager, will consist of "units," each containing one common share and one purchase warrant. Based on filings with the U.S. Securities and Exchange Commission (SEC), the offering price is estimated at $9.75 per unit, pegged to the stock's recent performance on the Canadian Securities Exchange (CSE).

For existing shareholders, the transition is designed to be seamless. Trading on the OTCQB under the symbol "INNPF" is expected to cease upon the NYSE American debut, but the company's shares will continue to trade on the CSE under its long-standing symbol "INNO." The company has assured stockholders that no action is required on their part for the uplisting to take effect.

Financial Health and Market Expectations

Innocan approaches its NYSE American debut with a complex financial profile that presents both compelling strengths and notable challenges. Despite a difficult year for its stock, which saw a decline of over 48% year-over-year, underlying financial metrics suggest a company with a robust operational foundation. According to an InvestingPro analysis, Innocan's overall financial health is rated as "GOOD," highlighting an impressive gross profit margin of 88.5% and a healthy current ratio of 3.72, which indicates strong short-term liquidity and an ability to cover its immediate liabilities.

However, this fundamental strength has yet to translate into profitability or positive investor sentiment, with analysts assigning the stock a neutral "Hold" rating. The company's struggles with cash flow and a negative P/E ratio have weighed on its valuation. The upcoming listing and offering are precisely the catalysts intended to address this disconnect. By accessing a larger pool of capital and a more diverse set of investors, Innocan hopes to fund its ambitious research and development pipeline, potentially turning the tide on its recent bearish stock performance and unlocking what some analyses suggest is an undervalued company.

The Science Driving the Strategy

At the heart of Innocan's long-term strategy is its LPT (Liposome Platform Technology), a sophisticated drug delivery system designed to overcome key challenges in cannabinoid-based medicine. The company's primary pharmaceutical focus is a CBD-loaded liposome platform for managing non-opioid pain. This technology encapsulates synthetic CBD within liposomes, which are microscopic fat-based vesicles, enabling a prolonged and controlled release of the active ingredient directly into the bloodstream. This method aims to provide consistent, exact dosing, improving bioavailability and therapeutic efficacy while minimizing side effects.

The potential market for such a technology is immense, particularly as the medical community actively seeks viable alternatives to addictive opioid painkillers. Innocan has been diligently building a protective moat around its innovations, with a portfolio of 31 published patents and applications across eight families. The company has already secured a patent in India for its LPT-CBD technology and has filed a divisional application in China, signaling a global intellectual property strategy.

Complementing its high-stakes pharmaceutical research is a revenue-generating wellness division. Through its 60% owned subsidiary, BI Sky Global Ltd., Innocan develops and markets a portfolio of self-care and beauty products, providing a steady stream of income that helps support the capital-intensive pharma R&D. This dual-pronged approach diversifies risk and provides a commercial foothold while its core therapeutic technologies mature.

Navigating the Regulatory Gauntlet

The most significant hurdle for any company in the CBD therapeutics space is the complex and evolving regulatory landscape, particularly in the United States. The U.S. Food and Drug Administration (FDA) maintains a stringent approval process for all new drugs, and CBD-based products are no exception. While the FDA has approved cannabis-derived drugs like Epidiolex for specific conditions, the pathway to market remains a rigorous, multi-year journey of preclinical and clinical trials to prove safety and efficacy.

Innocan appears to be navigating this environment with deliberate care. A notable sign of progress came from the FDA's Center for Veterinary Medicine (CVM), which granted Innocan a sponsor fee waiver for its LPT-CBD product for the second consecutive year. This waiver, intended to encourage the development of innovative animal drugs, applies to the company's research into treating chronic pain in dogs. While veterinary medicine is a different pathway than human medicine, this repeated engagement with the FDA is a positive indicator. It demonstrates that the agency recognizes the company's scientific approach and its potential to bring a novel therapeutic product to market, even if the initial application is for animal health.

Successfully bringing a CBD-based pain management solution to the human market will require navigating this same rigorous process on a much larger scale. The capital raised from the NYSE American listing will be critical in funding the expensive, multi-phase clinical trials required to gain FDA approval and finally bring its flagship technology to patients in need.